Eurofins BioPharma Product Testing (EBPT) in the US is a leading entity in the analytical testing of Cell and Gene Therapy, with its involvement dating back to 2010 at the Eurofins BPT Lancaster, PA location. Over the past decade, EBPT has developed a comprehensive business strategy catering to the analytical industry's needs, covering Raw Materials, Cell Banks, Plasmids, Viral Vectors, Genetically Modified Cells, CAR-T drug products, and iPSCs. The company has actively supported the growth of Cell and Gene Therapy through strategic investments, including the adoption of innovative technologies like droplet digital PCR, Analytical Ultracentrifugation , and Transmission Electron Microscope testing. These investments also involve dedicated facilities at various locations across the US.
MIT survey results address product and site characteristics that statistically correlate with quality performance.
Powdered self-emulsified dosage forms provide an attractive alternative to filled-capsule preparations, but the selection of a proper excipient is crucial.
Application of single-use technology in a parenteral facility for syringe filling.
The authors review developments in wet granulation using a twin-screw extruder.
This article examines European differences in GMP requirements for the acceptance of Certificates of Tests. The authors look at how pharmaceutical manufacturers can address the issues and suggest a US-compatible framework for GMPs that could be incorporated into EU requirements.
The authors describe a new assembly for bulk and final drug product filling operations.
For true freeze-drying cycle optimisation, information on the maximum allowable product temperature during primary drying is required.
Application of single-use technology in a parenteral facility for syringe filling.
Application of single-use technology in a parenteral facility for syringe filling.
MIT survey results address product and site characteristics that statistically correlate with quality performance.
In this article, the authors demonstrate that a normal-phase chromatographic method was stability-indicating for a water-sensitive prodrug. The stress conditions using aqueous and non-aqueous conditions were also compared to understand the information obtained with each approach.
Fixed-dose combinations (FDCs) reduce the number of pills that must be taken, but they have also been a topic of concern, mainly because of the perceived potential for increased adverse events. PTE speaks with researchers to explore the benefits and concerns of FDCs.
Risk levels should be considered when designing containment for pharmaceutical tableting equipment to enhance operator safety.
The use of aqueous cleaning in pharmaceutical manufacturing can provide numerous benefits in terms of effectiveness, minimal surface residue, and easier cleaning validation.
Assessing risk factors is key to implementing the new ICH Q3D guidelines for elemental impurities.
A look at the role of document management in the product life-cycle and how this can lead to the effective use of CTDs and e-CTDs when compiling compulsory regulatory submissions...
A risk-based approach is recommended for analytical method comparability for HPLC assay and impurities methods.
PIC/S reviews deficiencies found during inspections of API manufacturing facilities, harmonizes GMP standards, and provides training for inspectors worldwide.
Multilayer tablets: A piece of cake or just a passing fad? We bring experts together to find out.
Analytical tests, correlated with statistical techniques, are used to predict material behavior.
IQ Consortium representatives explore and define common industry approaches and practices for applying GMPs in early development, with a focus on stability.
PIC/S reviews deficiencies found during inspections of API manufacturing facilities, harmonizes GMP standards, and provides training for inspectors worldwide.
An analysis of controlled correspondence between generic-drug manufacturers and FDA reveals patterns in questions about specific drug chemistry topics and the response to information provided in FDA guidance documents.
IQ Consortium representatives explore and define common industry approaches and practices for applying GMPs in early development, with a focus on stability.
Zero-order release of a freely water-soluble active drug can be obtained using release-controlling polymers.
During the last few years, it has become increasingly apparent that many large pharmaceutical companies are moving their research and development operations to the US, leaving Europe with increasing numbers of smaller companies. This article briefly examines the possible motives for relocation, including the impact of regulation differences between the US and Europe.
Process design experimental data and risk assessments are used to predict expected process performance and establish process performance qualification acceptance criteria.